Florida Cancer Specialists & Research Institute Driving Global Progress in Cancer Care Discoveries

Thirteen Researchers Present Cutting-Edge Studies At 2025 ASCO^® Annual Meeting

2025 ASCO^® Annual Meeting abstracts featuring FCS research: 516, 2515, 2536 3000, 3009, 3010, 3011, 3030, 3033, 3041, 3042, 3124, 3151, 3517, 3553, 3579, 4006, 5502, 5503, 5523, 5551, 5599, 6024, 8519, 8589, 8598, e23219, e23550, TPS517, TPS1141, TPS3175, TPS5618, TPS8124, TPS8663

, /PRNewswire/ -- Findings from 34 clinical research studies conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) are among the groundbreaking scientific advances in cancer care that will be featured as oncology professionals from around the world gather this week at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting in Chicago.

Researchers from Florida Cancer Specialists & Research Institute (FCS) will present findings from 34 clinical research studies—highlighting breakthroughs in cancer care—at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting in Chicago. Thirteen FCS physicians and leaders from the statewide practice will share results from early- and late-phase trials conducted across Florida, including at three Phase 1 Drug Development Units.

Thirteen physicians and leaders from the statewide practice will present the outcomes of early and late-phase clinical trials concluded during the past year at three FCS Phase 1 Drug Development Units and FCS clinics throughout Florida.

Research conducted at FCS is made possible through valuable relationships with Sarah Cannon Research Institute, one of the world's leading clinical research organizations, and Paradigm Health, an AI-enabled clinical trial matching and recruitment platform.

FCS President & Managing Physician Lucio N. Gordan, MD said, "Our robust research program sets us apart from other community oncology practices and is a cornerstone of our mission to deliver convenient access to world-class cancer care."

"The research findings being presented span new approaches alongside cutting-edge targeted therapies," said FCS Director of Drug Development Manish R. Patel, MD. "We continue to uncover scientific knowledge that is advancing precision oncology and enhancing outcomes for multiple cancer types, including rare and advanced forms of the disease."

The following FCS principal investigators are first authors of five abstracts that will be presented throughout the meeting:

The following FCS principal investigators have co-authored 31 additional abstracts and publications of research results and other clinical findings featured throughout the annual meeting:

Cesar Augusto Perez, MD

Alexander Philipovskiy, MD, PhD

Judy Wang, MD

Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate
Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle
Artificial intelligence (XGBoost) in predicting outcomes among CAR-T therapy patients: The impact of malnutrition and comorbidities using the National Inpatient Sample (2020-2022).

Faye Yin, MD

Artificial intelligence (XGBoost) in predicting outcomes among CAR-T therapy patients: The impact of malnutrition and comorbidities using the National Inpatient Sample (2020-2022).
Survival of malignant peripheral nerve sheath tumor of the trachea, mediastinum, and other respiratory organs: Analysis of SEER database

"Our pioneering research and late-phase trials are transforming clinical practice," said Bradley Monk, MD, gynecologic oncologist and FCS medical director of late-phase clinical research. "Every discovery sharpens our ability to deliver more precise, effective treatments."

FCS Chief Executive Officer Nathan H. Walcker said, "The ASCO^® annual meeting showcases the top research of the year from around the globe and FCS is proud to again be recognized at the forefront of shaping the future of cancer care."

All abstracts and presentations are available to view at ASCO® 2025 Annual Meeting.

The American Society of Clinical Oncology (ASCO^®) represents nearly 50,000 physicians and oncology professionals representing 150 countries who care for people living with all forms of cancer. ASCO^® works to conquer cancer through research, education, policy and promotion of high quality and equitable patient care.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute